Cargando…

Optimizing the Dosing Regimens of Daptomycin Based on the Susceptible Dose-Dependent Breakpoint against Vancomycin-Resistant Enterococci Infection

Daptomycin, a lipopeptide antibiotic, is one of the therapeutic options used for the treatment of vancomycin-resistant enterococci (VRE). Recently, the Clinical and Laboratory Standards Institute (CLSI) M100 30th edition has removed the susceptibility (S) breakpoint for Enterococcus faecium and repl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santimaleeworagun, Wichai, Changpradub, Dhitiwat, Thunyaharn, Sudaluck, Hemapanpairoa, Jatapat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963552/ https://www.ncbi.nlm.nih.gov/pubmed/31795437 http://dx.doi.org/10.3390/antibiotics8040245

Ejemplares similares

Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection
por: Santimaleeworagun, Wichai, et al.
Publicado: (2021)

Optimizing the Dosing Regimens of Tigecycline against Vancomycin-Resistant Enterococci in the Treatment of Intra-abdominal and Skin and Soft Tissue Infections
por: Santimaleeworagun, Wichai, et al.
Publicado: (2020)

Clinical Impact of Vancomycin Treatment in Ampicillin-Susceptible Enterococci Bloodstream Infections
por: Hemapanpairoa, Jatapat, et al.
Publicado: (2022)

Vancomycin-resistant enterococcal infection in a Thai university hospital: clinical characteristics, treatment outcomes, and synergistic effect
por: Hemapanpairoa, Jatapat, et al.
Publicado: (2019)

Does Vancomycin Resistance Increase Mortality? Clinical Outcomes and Predictive Factors for Mortality in Patients with Enterococcus faecium Infections
por: Hemapanpairoa, Jatapat, et al.
Publicado: (2021)

Is Early Monitoring Better? Impact of Early Vancomycin Exposure on Treatment Outcomes and Nephrotoxicity in Patients with Methicillin-Resistant Staphylococcus aureus Infections
por: Chattaweelarp, Thanawat, et al.
Publicado: (2020)

2284. Treatment and Clinical Outcomes Among Infected Patients with Colistin-resistant Klebsiella pneumoniae Bacteremia.
por: Prawang, Abhisit, et al.
Publicado: (2019)

Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant Acinetobacter baumannii: Improved Efficacy or Decreased Risk of Nephrotoxicity?
por: Saelim, Weerayuth, et al.
Publicado: (2021)

The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant Klebsiella pneumoniae Isolates
por: Nulsopapon, Parnrada, et al.
Publicado: (2021)

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa
por: Nasomsong, Worapong, et al.
Publicado: (2022)

Correction: Nulsopapon et al. The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant Klebsiella pneumoniae Isolates. Antibiotics 2021, 10, 736
por: Nulsopapon, Parnrada, et al.
Publicado: (2022)

In vitro activity of colistin mono- and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital
por: Lertsrisatit, Yongyut, et al.
Publicado: (2017)

Antimicrobials as Single and Combination Therapy for Colistin-Resistant Pseudomonas aeruginosa at a University Hospital in Thailand
por: Pungcharoenkijkul, Supanun, et al.
Publicado: (2020)

Vancomycin Area under the Curve and Pharmacokinetic Parameters during the First 24 Hours of Treatment in Critically Ill Patients using Bayesian Forecasting
por: Pongchaidecha, Manat, et al.
Publicado: (2020)

322 Vancomycin-resistant Enterococci with Reduced Daptomycin Susceptibility in Singapore: Prevalence and Associated Factor
por: Chow, Angela, et al.
Publicado: (2014)

In vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant Enterococci
por: Tong, Jiepeng, et al.
Publicado: (2021)

The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Klebsiella pneumoniae Clinical Isolates Harboring Different Carbapenemase Types in a Thai University Hospital
por: Nasomsong, Worapong, et al.
Publicado: (2021)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

First-Line Antiretroviral Regimen Failure and Determinants in an Urban HIV Clinic at Phramongkutklao Hospital, Bangkok, Thailand: 20 Years Experience
por: Nasomsong, Worapong, et al.
Publicado: (2021)

Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience
por: McKinnell, James A., et al.
Publicado: (2015)

Should High-dose Daptomycin be an Alternative Treatment Regimen for Enterococcal Endocarditis?
por: Peghin, Maddalena, et al.
Publicado: (2019)

Nosocomial Infection with Vancomycin-dependent Enterococci
por: Tambyah, Paul A., et al.
Publicado: (2004)

Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
por: Kanchanasurakit, Sukrit, et al.
Publicado: (2020)

Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol
por: Zarogoulidis, Paul, et al.
Publicado: (2014)

Vancomycin-resistant enterococci: eradication using vancomycin?
por: Van Prehn, J, et al.
Publicado: (2014)

Comparison of Race‐Based and Non–Race‐Based Equations for Kidney Function Estimation in Critically Ill Thai Patients for Vancomycin Dosing
por: Sitaruno, Sirima, et al.
Publicado: (2022)

1539. Dalbavancin, Vancomycin, and Daptomycin Alone and in Combination with Cefazolin Against Vancomycin Intermediate-Resistant (VISA) and Daptomycin Non-Susceptible (DNS) Staphylococcus aureus
por: Abdul-Mutakabbir, Jacinda, et al.
Publicado: (2019)

Emergence of vancomycin-resistant enterococci.
por: Rice, L B
Publicado: (2001)

Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)
por: Sader, Helio S, et al.
Publicado: (2007)

Risk of vancomycin-resistant enterococci bloodstream infection among patients colonized with vancomycin-resistant enterococci
por: Kara, Ahu, et al.
Publicado: (2014)

Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation
por: Lewis, Susan J., et al.
Publicado: (2023)

High-level Aminoglycoside Resistance and Reduced Susceptibility to Vancomycin in Nosocomial Enterococci
por: Adhikari, Luna
Publicado: (2010)

Antimicrobial susceptibility pattern of vancomycin resistant enterococci to newer antimicrobial agents
por: Gupta, Varsha, et al.
Publicado: (2015)

Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin
por: Shlezinger, Mor, et al.
Publicado: (2019)

Susceptibility of Glycopeptide-Resistant Enterococci to Linezolid, Quinupristin/dalfopristin, Tigecycline and Daptomycin in a Tertiary Greek Hospital
por: Maraki, Sofia, et al.
Publicado: (2014)

A Pharmacovigilance Analysis of Daptomycin Use Based on CLSI Susceptible Dose-Dependent Category
por: Zhang, Ming M., et al.
Publicado: (2023)

1084. Comparative Outcomes Among Patients Receiving Varying Daptomycin Dosing Regimens in Hemodialysis
por: Maxwell, Tyler, et al.
Publicado: (2021)

166. Evaluation of Daptomycin Prescribing Practices Based on Microbiologic Susceptibility Determination of “Susceptible-Dose Dependent” (SDD)
por: Rowley, Amy, et al.
Publicado: (2021)

Research into biocompatibility and cytotoxicity of daptomycin, gentamicin, vancomycin and teicoplanin antibiotics at common doses added to bone cement
por: Kılınç, Seyran, et al.
Publicado: (2020)

Vancomycin-resistant Enterococci, Mexico City
por: Cuellar-Rodríguez, Jennifer, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_4213m0uq98giseki1gj9qrg913